InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and is committed to becoming a global leader in revolutionary cancer therapies.
Company founded Tens of millions USD of A round raised Preliminary R&D pipeline established
Opening of InxMed Shanghai & Beijing offices
IN10018 Received US FDA IND Approval
Achieved clinical collaboration with Roche for IN10018 co-development
IN10018 Phase I Clinical Trial in China approved
Achieved clinical collaboration with Merck for IN10018 co-development
With in-depth knowledge of disease biology at the core of our innovation, InxMed is committed to becoming a global leader in revolutionary cancer therapies
To invent personalized medicines with a global impact based on our integrated translational R&D platform
InxMed (Beijing) Co., Ltd.
InxMed (Nanjing) Co., Ltd.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
Tel: +86 25-58251030
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing